In contrast, we and others have shown that certain immune biomarkers assessed within the first months are useful to identify SOT recipients at increased risk of developing cancer in the mid- and long-term follow-up, such as CD4+ and CD8+ T-cell counts [6, 28], monocytic myeloid-derived suppressor cells [29] or TTV DNAemia [22]. This evidence concerns the gene CD4 and cancer.